The Second Wave: Why GSK's mRNA Flu Vaccine Push Could Reshape a Market Moderna Just Opened

Moderna spent years building the case that mRNA technology could do more than fight COVID-19. On August 6, 2026, the FDA approved mFlusiva, the first mRNA-based seasonal flu vaccine, for adults aged 50 and older. The market had barely absorbed that milestone when GSK announced, on September 1, that it was advancing its own mRNA flu vaccine candidate into a pivotal Phase 3 trial. The race for the next generation of influenza protection is now officially underway, and the scientific argument GSK is making is more ambitious than anything Moderna brought to market.

The distinction matters. Moderna's mFlusiva targets three hemagglutinin proteins, the surface antigen that conventional flu vaccines have always focused on. GSK's candidate, FLUm3HA.b-3NA, targets both hemagglutinin and neuraminidase, the two primary surface proteins on the influenza virus. That dual-antigen approach is not a minor formulation tweak. It represents a fundamentally different theory of protection, one that the field has debated for years but never tested at scale in a pivotal trial.

Why Neuraminidase Has Always Been the Overlooked Antigen

Conventional flu vaccines have focused almost exclusively on hemagglutinin because it is the protein the virus uses to attach to human cells, and antibodies against it can block infection. Neuraminidase plays a different role: it helps newly formed virus particles escape from infected cells and spread to neighboring tissue. Antibodies against neuraminidase do not prevent infection in the same way, but evidence has accumulated over decades suggesting they reduce illness severity and may be more effective at interrupting transmission. The problem has always been that manufacturing neuraminidase antigens at scale, with consistent quality, is technically difficult using conventional egg-based or cell-based production methods.

mRNA changes that calculus. Because mRNA vaccines encode instructions for the immune system to produce the antigen itself, rather than requiring manufacturers to grow and purify the protein directly, the platform is better suited to encoding multiple antigens simultaneously. GSK's Phase 2 trial, which enrolled 971 adults across younger and older age groups, tested candidates encoding both HA and NA from influenza A and B strains. The results showed higher immune responses against all flu types compared with both standard-dose and high-dose licensed comparators. The FDA found the data compelling enough to grant fast-track designation in July 2026.

The Market GSK Is Entering, and Why It Needs to Win

GSK's flu vaccine business shrank by approximately 25 percent last year, squeezed by competitive pressure in the United States. The company's existing portfolio of conventional flu shots faces the same structural challenge that has plagued the entire category for years: variable effectiveness that has ranged from 20 to 60 percent over the past decade and a half, depending on how well the annual strain selection matches what actually circulates. That unpredictability has eroded confidence among both prescribers and patients, and it has created an opening for next-generation approaches that can offer more consistent and broader protection.

The mRNA platform addresses part of that problem through manufacturing speed. Because mRNA vaccines can be produced more rapidly than conventional shots, developers can wait longer into the surveillance season before finalizing the strain composition, reducing the mismatch risk that has historically driven the worst-performing years. But GSK is betting that the more durable competitive advantage lies in the antigen strategy itself. A vaccine that generates robust immunity against both HA and NA, across A and B strains, could offer a meaningfully different protection profile than anything currently on the market, including mFlusiva.

What the Phase 3 Trial Will Need to Show

The pivotal study GSK is launching this month will be the first late-stage trial of any mRNA flu vaccine designed around dual-antigen targeting. That is a significant scientific milestone, but it also means the trial is entering territory without a clear precedent for what success looks like. Regulatory agencies have historically evaluated flu vaccines on immunogenicity endpoints, specifically whether the vaccine generates antibody titers that meet pre-specified thresholds against each strain. Whether a dual-antigen approach that generates strong responses against both HA and NA will translate into superior clinical protection against confirmed influenza illness is the question the Phase 3 data will need to answer.

The scale of the unmet need is not in dispute. The 2025-2026 flu season in the United States produced approximately 32 million cases, 390,000 hospitalizations, and 24,000 deaths, according to CDC data. Globally, influenza causes roughly one billion cases and up to 650,000 deaths annually. Those numbers have remained stubbornly consistent despite decades of vaccination campaigns, in part because the vaccines available have never been good enough to drive the kind of population-level protection that would meaningfully bend the curve.

The Competitive Landscape and What It Means for Patients

Moderna's mFlusiva approval established that the regulatory pathway for mRNA flu vaccines is navigable, and that the FDA is willing to evaluate these products on immunogenicity data rather than requiring large-scale efficacy trials against confirmed influenza. That precedent benefits GSK, which can now design its Phase 3 program with a clearer understanding of what the agency expects. The question is whether the dual-antigen approach will generate the kind of differentiated immunogenicity data that justifies a distinct regulatory and commercial position, or whether the incremental benefit over mFlusiva will be difficult to demonstrate convincingly.

Moderna, for its part, explored HA and NA combination candidates internally before pausing that line of development as part of a broader pipeline restructuring. The fact that GSK is now advancing precisely that approach, with Phase 2 data in hand and a Phase 3 trial starting this month, suggests the scientific case for dual-antigen targeting is strong enough to survive the competitive pressures that led Moderna to step back. Whether it is strong enough to produce a vaccine that genuinely outperforms the current standard of care, in a disease that has resisted improvement for generations, is the question that the next several years of clinical development will answer.

For the roughly one billion people who contract influenza each year, the answer matters more than any competitive dynamic between pharmaceutical companies. The mRNA platform has already demonstrated, in COVID-19 and now in the first approved flu vaccine, that it can move faster and generate stronger immune responses than conventional approaches. GSK's Phase 3 trial is a test of whether it can also move smarter, by targeting the biology of influenza protection more completely than any vaccine that has come before it.